ClinicalTrials.gg
CompletedNCT03693300Updated Jun 18, 2024Results posted

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

A Phase 2 interventional study of Durvalumab in Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
31st of 94
117 · median 74
Started
2019
with 7 others
Phase 2
58 of 94
11 open now
Registered
34th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 31st largest by enrollment, is one of 8 that started in 2019, is one of 58 in phase 2, and was the 34th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks [q4w] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based sequential chemoradiation therapy (sCRT). This study will be conducted in Europe and North America.

Read the detailed description

This is a Phase II, open-label, multi-centre study to determine safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) monotherapy in participants with unresectable Stage III NSCLC who have not progressed following definitive, platinum-based sCRT. Approximately, 150 participants will be treated with the study drug in Europe and North America. Participants will be in complete response (CR), partial response (PR), or have stable disease (SD) following definitive, platinum-based sCRT, as assessed by the Investigator and further supported by the screening imaging radiological assessment. Participants must not have progressed following definitive, platinum-based sCRT; radiation therapy must be completed within 42 days prior to first Investigational product (IP) dose administration. Participants must have histologically- or cytologically-documented NSCLC and locally-advanced, unresectable Stage III disease. Participants will be treated with the study drug in 2 cohorts: approximately 100-120 participants in the World Health Organization/Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) 0 to 1 Cohort and up to 30 participants in the WHO/ECOG PS 2 Cohort.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • Stage III Non-Small Cell Lung Cancer
  • Durvalumab
  • IV infusion immunoglobulin G (IgG)
  • Antibody-dependent cellular cytotoxicity
  • Complement-dependent cytotoxicity
  • Monotherapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.
  3. Provision of signed and dated written genetic informed consent prior to collection of sample for genetic analysis (optional).
  4. 18 years or older at the time of signing the ICF.
  5. - or cytologically-documented NSCLC with locally-advanced, unresectable Stage III disease (according to the IASLC Staging Manual Version 8 [IASLC 2016]). Positron emission tomography (PET)/CT, MRI of the brain, and endobronchial ultrasound with are highly encouraged at diagnosis.
  6. Receipt of sCRT which must have been completed within 42 days prior to first IP dose administration in the study.

    1. The platinum-based chemotherapy regimen must contain cisplatin or carboplatin and 1 of the following agents: etoposide, vinblastine, vinorelbine, a taxane (paclitaxel or docetaxel), or pemetrexed, according to the local standard of care (SoC) regimens. Platinum-based chemotherapy containing cisplatin or carboplatin and gemcitabine is permitted under certain conditions - refer to bullet point 6(b).
    2. Patients must have received at least 2 cycles of platinum-based chemotherapy before radiation therapy. The interval between administration of the last dose of chemotherapy regimen and start of radiation therapy must be no more than 6 weeks. Consolidation chemotherapy after radiation is not permitted.

    (i) If the patient's platinum-based chemotherapy contained gemcitabine, no overlap between chemotherapy and radiation therapy is permitted.

    (ii) If the patient's platinum-based chemotherapy contained any of the agents listed in (a) other than gemcitabine, an overlap of 1 cycle of chemotherapy and radiation therapy is acceptable.

    (c) Patients must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy). Sites are encouraged to adhere to mean organ radiation dosing as follows: (i) Mean lung dose \<20 Gy and/or V20 \<35%; (ii) Mean oesophagus \<34 Gy; (iii) Heart V45 \<35% or V30 \<30%. Note: Sites should be aware of the recent RTOG 0617 Study data demonstrating that doses higher than 60 Gy may be associated with greater toxicity and worse efficacy.

    (d) Patients with PS 2 or chronic lung disease (pulmonary emphysema or ) must have received a V20 \<25%.

  7. Patients must not have progressed following platinum-based sCRT, as per Investigator assessed 1.1 criteria. . In order to assess disease progression, the baseline imaging (CT/MRI) used for Screening purposes should be compared against the most recently performed scan that allows physician assessment as per RECIST 1.1 criteria. If an intermediate scan taken between chemotherapy and radiotherapy is available and that scan is suitable for physician assessment as per RECIST 1.1 criteria, then this scan should be used.

    1. Patients with and/or non-measurable and/or no evidence of disease (NED) assessed at baseline by CT/MRI will be entered in this study.
    2. Prior irradiated lesions may be considered measurable and selected as TLs provided they fulfil the other criteria for measurability.
  8. Must have a of at least 12 weeks at enrolment.
  9. WHO/ECOG PS ≤2.
  10. Adequate organ and marrow function at enrolment as defined below. These parameters should be achieved without augmentation by growth factors, transfusions, or infusions within 14 days of screening unless required for SoC:

    1. ≥9.0 g/dL;
    2. >1.0 × 109/L;
    3. count >75 × 109/L;
    4. Serum ≤1.5 × (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician.
    5. (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.
    6. Measured >40 mL/min or calculated creatinine clearance >40 mL/min as determined by Cockcroft-Gault (using actual body weight) (Cockcroft and Gault 1976).

Males:

Creatinine clearance (mL/min) = Weight (kg) × (140 Age) 72 × serum creatinine (mg/dL)

Females:

Creatinine clearance (mL/min) = Weight (kg) × (140 Age) × 0.85 72 × serum creatinine (mg/dL)

11 Body weight >30 kg at enrolment and first IP dose administration. 12 Male or female. 13 Evidence of status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

  1. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
  2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

Exclusion criteria

Exclusion criteria:

  1. Patients with locally-advanced NSCLC whose disease has progressed following platinum based sCRT.
  2. Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumours.
  3. Mixed small-cell lung cancer and NSCLC histology.
  4. History of allogeneic organ transplantation.
  5. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    1. Patients with vitiligo or alopecia.
    2. Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.
    3. Any chronic skin condition that does not require systemic therapy.
    4. Patients without active disease in the last 5 years at enrolment may be included but only after consultation with the Study Physician.
    5. Patients with celiac disease controlled by diet alone.
  6. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written .
  7. History of another primary except for:

    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
  8. History of .
  9. History of active primary immunodeficiency.
  10. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive hepatitis B surface antigen [HbsAg] result), virus (HCV), or (HIV) (positive HIV 1/2 antibodies). Patients with a past or resolved hepatitis B virus (HBV) infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
  11. Any unresolved toxicity of Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.

    1. Patients with Grade ≥2 neuropathy or Grade ≥2 lymphopenia will be evaluated on a case-by-case basis after consultation with the Study Physician.
    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab (MEDI4736) may be included only after consultation with the Study Physician.
  12. Known allergy or to durvalumab (MEDI4736) or any of the IP .
  13. Patients who have received cCRT for locally-advanced NSCLC, or who received sCRT with at least 2 concomitant CRT cycles. Prior surgical resection (ie, Stage I or II) is permitted.

    Note: Patients whose platinum-based chemotherapy contained gemcitabine and who received sCRT with at least 1 concomitant CRT cycle are excluded from this study.

  14. Receipt of within 30 days prior to the first dose of IP.

    Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.

  15. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

    Note: Local surgery of isolated lesions for palliative intent is acceptable.

  16. Prior exposure to immune-mediated therapy, including but not limited to, other anti , anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.
  17. Current or prior use of medication within 14 days before the first dose of IP. The following are exceptions to this criterion:

    1. Intranasal, inhaled, topical , or local steroid injections (eg, intra articular injection);
    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent;
    3. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  18. Previous IP assignment in the present study.
  19. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.
  20. Participation in another clinical study with an IP during the 4 weeks prior to the first IP dose administration.
  21. Prior randomisation or treatment in a previous durvalumab (MEDI4736) ± tremelimumab clinical study regardless of treatment arm assignment.
  22. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective from screening to 90 days after the last dose of IP.
  23. Judgment by the Investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements.
  24. Genetic research study (optional):

Exclusion criteria for participation in the optional (DNA) genetic research component of the study include:

  1. Previous bone marrow transplant.
  2. Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    WHO/ECOG PS 0 to 1 Cohort

    100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

    Drug: Durvalumab

  • Experimental
    WHO/ECOG PS 2 Cohort

    up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

    Drug: Durvalumab

Interventions

  • Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)

    Safety and tolerability of Durvalumab as defined by Grade 3 and Grade 4 TRAEs following IV infusion administration was assessed.

    Time frame: Up to 6 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    The efficacy of Durvalumab (MEDI4736) treatment in terms of PFS. PFS was defined as the time from the first date of treatment until the date of objective disease progression based on Investigator's assessment according to RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression.

    Time frame: From the first date of treatment until the date of objective disease progression or death (approximately upto 48 months)

  2. Percentage of Patients Progression-free at 12 Months

    The percentage of patients treated with Durvalumab who are progression-free was estimated. PFS12 according to RECIST 1.1 as assessed by the Investigator.

    Time frame: From the first date of treatment until the date of objective disease progression or death (upto 12 months)

  3. Overall Survival (OS)

    The efficacy of Durvalumab (MEDI4736) treatment in terms of OS were assessed. OS was defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time frame: From the first date of treatment until death due to any cause (approximately upto 48 months)

  4. Percentage of Patients Alive

    Percentage of patients alive at 12 months, 24 months, and 36 months were estimated.

    Time frame: From the first date of treatment until the date of objective disease progression or death (12 months, 24 months, and 36 months)

  5. Objective Response Rate (ORR)

    The efficacy of Durvalumab (MEDI4736) treatment in terms of ORR were assessed. ORR (based on Investigator assessed response to treatment of complete response (CR) and partial response (PR) as per RECIST 1.1 criteria), together with the corresponding 95% CI, was reported for patients. Objective response is complete response (CR), or partial response (PR) confirmed by a follow-up visit at least 4 weeks after. Both visits contributing to response should have occurred before any further anti-cancer therapy, in order for the patient to be considered a responder. Responses that occurred after the start of subsequent anti-cancer therapy were not included in the numerator. Response excluded unconfirmed response. Participants with unconfirmed responses include those whose CR, or PR don't have a confirmed response. These responses occur at any time during the study, recur after anti-cancer therapy, and these participants were missing for a follow-up visit 4 weeks after.

    Time frame: From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 52 weeks and every 12 weeks (q12w) ±1 week until disease progression (approximately upto 48 months)

  6. Duration of Response (DOR) From Onset of Response

    The efficacy of Durvalumab (MEDI4736) treatment in terms of DoR were assessed. DoR was defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression. If a patient did not progress following a response, then the patients' DoR was censored at the PFS censoring time.

    Time frame: From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 52 weeks and q12w ±1 week until disease progression (approximately upto 48 months)

  7. Lung Cancer Mortality

    The efficacy of durvalumab (MEDI4736) treatment in terms of lung cancer mortality was assessed. Lung Cancer Mortality was defined as the time from the date of treatment start until death due to lung cancer. Any patient not known to have died due to lung cancer will be censored based on the last recorded date on which the patient was known to be alive or died due to reason other than lung cancer.

    Time frame: From date of treatment start until death due to lung cancer (approximately upto 48 months)

  8. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs)

    The safety and tolerability profile of Durvalumab(MEDI4736) treatment, including all AEs were assessed.

    Time frame: Until the final visit (upto 48 months)

07

Results

Posted Oct 7, 2022

Participant flow

The study was conducted from 16 April 2019 to 21 April 2023 at 25 sites in the United States of America (USA), France, Germany, Italy, Spain, and the United Kingdom.

Participant flow — Overall Study
MilestoneDurvalumab Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1Durvalumab ECOG PS 2
Started1143
Completed561
Not completed582
Withdrew: Withdrawal by subject60
Withdrew: Death502
Withdrew: Lost to follow-up20

Outcome measures

PrimaryNumber of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)

Safety and tolerability of Durvalumab as defined by Grade 3 and Grade 4 TRAEs following IV infusion administration was assessed.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)
ParticipantsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Any possibly related AEs of CTCAE Grade 3 or Grade 4707
Any possibly related AEs of Grade 3 or Grade 4 with onset date within 6 months of the first dose505
Statistical analysis
  • Durvalumab ECOG PS 0 or 1 · Proportion (%): 6.1 · 95% CI 2.50 to 12.2495% CI were based on the Clopper-Pearson method.
  • Durvalumab ECOG PS 2 · Proportion (%): 0 · 95% CI 0.00 to 70.7695% CI were based on the Clopper-Pearson method.
  • Durvalumab Total · Proportion (%): 6.0 · 95% CI 2.44 to 11.9495% CI were based on the Clopper-Pearson method.
  • Durvalumab ECOG PS 0 or 1 · Proportion (%): 4.4 · 95% CI 1.44 to 9.9495% CI were based on the Clopper-Pearson method.
  • Durvalumab ECOG PS 2 · Proportion (%): 0 · 95% CI 0.00 to 70.7695% CI were based on the Clopper-Pearson method.
  • Durvalumab Total · Proportion (%): 4.3 · 95% CI 1.40 to 9.6995% CI were based on the Clopper-Pearson method.
SecondaryProgression-free Survival (PFS)

The efficacy of Durvalumab (MEDI4736) treatment in terms of PFS. PFS was defined as the time from the first date of treatment until the date of objective disease progression based on Investigator's assessment according to RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression.

Time frame:
From the first date of treatment until the date of objective disease progression or death (approximately upto 48 months)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Progression-free Survival (PFS)13.1 (7.36 to 19.91)3.7 (1.81 to NA)13.1 (7.36 to 19.91)
SecondaryPercentage of Patients Progression-free at 12 Months

The percentage of patients treated with Durvalumab who are progression-free was estimated. PFS12 according to RECIST 1.1 as assessed by the Investigator.

Time frame:
From the first date of treatment until the date of objective disease progression or death (upto 12 months)
Reported as:
Number · Percentage of patient
Percentage of Patients Progression-free at 12 Months
Percentage of patientDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Percentage of Patients Progression-free at 12 Months51.1 (41.29 to 60.02)33.3 (0.90 to 77.41)50.6 (40.97 to 59.45)
SecondaryOverall Survival (OS)

The efficacy of Durvalumab (MEDI4736) treatment in terms of OS were assessed. OS was defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

Time frame:
From the first date of treatment until death due to any cause (approximately upto 48 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Overall Survival (OS)39.0 (30.59 to NA)12.3 (4.96 to NA)39.0 (30.59 to NA)
SecondaryPercentage of Patients Alive

Percentage of patients alive at 12 months, 24 months, and 36 months were estimated.

Time frame:
From the first date of treatment until the date of objective disease progression or death (12 months, 24 months, and 36 months)
Reported as:
Number · Percentage of patient
Percentage of Patients Alive
Percentage of patientDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Survival at 12 months83.9 (75.73 to 89.57)66.7 (5.41 to 94.52)83.5 (75.36 to 89.15)
Survival at 24 months68.2 (58.54 to 76.00)33.3 (0.90 to 77.41)67.2 (57.73 to 75.08)
Survival at 36 months57.2 (46.94 to 66.20)NA (NA to NA)56.5 (46.41 to 65.46)
SecondaryObjective Response Rate (ORR)

The efficacy of Durvalumab (MEDI4736) treatment in terms of ORR were assessed. ORR (based on Investigator assessed response to treatment of complete response (CR) and partial response (PR) as per RECIST 1.1 criteria), together with the corresponding 95% CI, was reported for patients. Objective response is complete response (CR), or partial response (PR) confirmed by a follow-up visit at least 4 weeks after. Both visits contributing to response should have occurred before any further anti-cancer therapy, in order for the patient to be considered a responder. Responses that occurred after the start of subsequent anti-cancer therapy were not included in the numerator. Response excluded unconfirmed response. Participants with unconfirmed responses include those whose CR, or PR don't have a confirmed response. These responses occur at any time during the study, recur after anti-cancer therapy, and these participants were missing for a follow-up visit 4 weeks after.

Time frame:
From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 52 weeks and every 12 weeks (q12w) ±1 week until disease progression (approximately upto 48 months)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Number of patients with response24024
Number of patients with unconfirmed response505
SecondaryDuration of Response (DOR) From Onset of Response

The efficacy of Durvalumab (MEDI4736) treatment in terms of DoR were assessed. DoR was defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression. If a patient did not progress following a response, then the patients' DoR was censored at the PFS censoring time.

Time frame:
From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 52 weeks and q12w ±1 week until disease progression (approximately upto 48 months)
Reported as:
Median · Weeks
Duration of Response (DOR) From Onset of Response
WeeksDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Duration of Response (DOR) From Onset of ResponseNA (NA to NA)—NA (NA to NA)
SecondaryLung Cancer Mortality

The efficacy of durvalumab (MEDI4736) treatment in terms of lung cancer mortality was assessed. Lung Cancer Mortality was defined as the time from the date of treatment start until death due to lung cancer. Any patient not known to have died due to lung cancer will be censored based on the last recorded date on which the patient was known to be alive or died due to reason other than lung cancer.

Time frame:
From date of treatment start until death due to lung cancer (approximately upto 48 months)
Reported as:
Median · Months
Lung Cancer Mortality
MonthsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Lung Cancer Mortality41.8 (36.50 to NA)NA (4.96 to NA)41.8 (36.50 to NA)
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs)

The safety and tolerability profile of Durvalumab(MEDI4736) treatment, including all AEs were assessed.

Time frame:
Until the final visit (upto 48 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs)
ParticipantsDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
Any AE1083111
Any AE possibly related to treatment87390
Any AE of CTCAE Grade 3 or Grade 432032
Any AE of CTCAE Grade 3 or Grade 4, possibly related to treatment707
Any AE with outcome of death303
Any AE with outcome of death, possibly related to treatment101
Any SAE (including events with outcome of death)32032
Any SAE (including events with outcome of death), possibly related to treatment707
Any AE leading to discontinuation of treatment32032
Any AE leading to discontinuation of treatment, possibly related to treatment19019
Any AE leading to treatment interruption52153
Any AE leading to treatment interruption, possibly related to treatment24125
Any AESI or AEPI (including events with outcome of death)86389
Any AESI or AEPI (including events with outcome of death), possibly related to treatment73275
Any imAE48250
Any imAE, possibly related to treatment43245
Any imAE as assessed by Investigator64165
Any imAE as assessed by Investigator, possibly related to treatment64165

Adverse events

Collected over Upto 48 months. Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab ECOG PS 0 or 150/114 (43.9%)32/114 (28.1%)106/114 (93%)
Durvalumab ECOG PS 22/3 (66.7%)0/3 (0%)3/3 (100%)
Durvalumab Total52/117 (44.4%)32/117 (27.4%)109/117 (93.2%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
PneumoniaInfections and infestations5/1140/35/117
PneumonitisRespiratory, thoracic and mediastinal disorders5/1140/35/117
Atrial fibrillationCardiac disorders2/1140/32/117
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1140/32/117
Radiation pneumonitisInjury, poisoning and procedural complications2/1140/32/117
Covid-19Infections and infestations1/1140/31/117
Covid-19 pneumoniaInfections and infestations1/1140/31/117
InfluenzaInfections and infestations1/1140/31/117
OsteomyelitisInfections and infestations1/1140/31/117
Pneumocystis jirovecii pneumoniaInfections and infestations1/1140/31/117
Most frequent other events
Showing 10 of 88
Most frequent other events
EventDurvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Durvalumab Total
CoughRespiratory, thoracic and mediastinal disorders43/1142/345/117
DyspnoeaRespiratory, thoracic and mediastinal disorders27/1142/329/117
PruritusSkin and subcutaneous tissue disorders19/1142/321/117
AstheniaGeneral disorders29/1142/331/117
HypothyroidismEndocrine disorders15/1141/316/117
Decreased appetiteMetabolism and nutrition disorders14/1141/315/117
HyperglycaemiaMetabolism and nutrition disorders7/1141/38/117
HeadacheNervous system disorders17/1141/318/117
HypertensionVascular disorders7/1141/38/117
PneumonitisRespiratory, thoracic and mediastinal disorders16/1141/317/117

Baseline characteristics

The safety analysis set consisted of all patients who received at least one dose of (partial or in full) of study drug.

Age, Continuous
Age, Continuous(years)Durvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Total
Mean67.0 ± 8.4665.0 ± 12.0066.9 ± 8.50
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Total
Female43144
Male71273
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Total
Hispanic or Latino101
Not Hispanic or Latino1033106
Unknown or Not Reported10010
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab ECOG PS 0 or 1Durvalumab ECOG PS 2Total
White1013104
Unknown13013
08

Study locations

28 sites
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Creteil, 94010, France
  • Research Site
    Paris Cedex 05, 75248, France
  • Research Site
    Saint Priest en Jarez, 42270, France
  • Research Site
    Toulouse Cedex 9, 31400, France
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Grosshansdorf, 22927, Germany
  • Research Site
    Hamm, 59063, Germany
  • Research Site
    Hannover, 30459, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Avellino, 83100, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Parma, 43126, Italy
  • Research Site
    Roma, 00152, Italy
  • Research Site
    Barcelona, 08907, Spain
  • Research Site
    Guadalajara, 19002, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Sevilla, 41013, Spain
  • Research Site
    Valencia, 46015, Spain
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Middlesborough, TS4 3BW, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Sheffield, S10 2SJ, United Kingdom
  • Research Site
    Stoke on Trent, ST4 6QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Dec 2022, 43 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 43 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Oct 2, 2018
StartActual
Apr 16, 2019
Primary completionActual
Dec 13, 2022
CompletionActual
Apr 21, 2023
Results first posted
Oct 7, 2022
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03693300
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Apr 16, 2019
Primary completion
Dec 13, 2022
Completion
Apr 21, 2023
Results posted
Oct 7, 2022
Last update
Jun 18, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion